Discrepancies in low-value practices across cardiovascular disease prevention guidelines. A narrative review
Authors:
- Carlos BrotonsCarlos Brotons
- Irene MoralIMIrene Moral
- Tom AxelrodTATom Axelrod
- John Brandt BrodersenJBJohn Brandt Brodersen
- Carlos MartinsCarlos Martins
- Serdar ÖztoraSÖSerdar Öztora
- Iva PetričušićIPIva Petričušić
- Veerle PiessensVPVeerle Piessens
- Carlen ReyesCRCarlen Reyes
- Laura Rodriguez-BenitoLRLaura Rodriguez-Benito
Open Access
- 21 September 2026
- journal article
- review article
- Published by Taylor & Francis in European Journal of General Practice
- Vol. 32 (1) , 2729221
Abstract
Low-value practices are interventions that do not provide health benefits due to lack of effectiveness or associated risks that outweigh the potential benefits. The purpose of this study is to demonstrate discrepancies across various cardiovascular prevention guidelines published by numerous institutions and organisations, and establish an objective overview of the current state of the art and formulate recommendations for general practitioners. A narrative review of clinical practice guidelines for CVD prevention published in English between January 2017 and December 2025 was conducted. Searches focused on major European, British, North American, and Australian scientific societies; only guidelines containing explicit recommendations on low-value or unnecessary practices were included. We identified the scientific evidence supporting these recommendations and searched for ongoing clinical trials - specifically in cases where recommendations were based on a single randomised trial, large non-randomised studies, retrospective data, or expert opinion. Guidelines show significant discrepancies regarding recommendations for low-value practices. These primarily relate to the evaluation of the coronary artery calcium (CAC) score, determination of lipoprotein(a) (Lp(a)), screening for abdominal aortic aneurysm (AAA), and the initiation of lipid-lowering treatment in older adults. Controversy and uncertainty were most evident when recommendations were based on non-randomised clinical trials or expert opinion. While some guidelines align, others exhibit clear discrepancies, illustrating the uncertainty of the scientific evidence and differing interpretations. Until robust evidence from high-quality clinical trials becomes available, clinicians should exercise caution regarding certain screening procedures and therapeutic interventions in CVD prevention within general practice.Keywords
This publication has 47 references indexed in Scilit:
- Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery DiseaseJAMA, 2025
- Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)American Heart Journal, 2025
- Practices of low value or unnecessary practices in vascular preventionHipertensión y Riesgo Vascular, 2025
- Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)American Heart Journal, 2022
- Aspirin Use to Prevent Cardiovascular DiseaseJAMA, 2022
- 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in AdultsCanadian Journal of Cardiology, 2021
- Screening for Abdominal Aortic AneurysmJAMA, 2019
- Risk Assessment for Cardiovascular Disease With Nontraditional Risk FactorsJAMA, 2018
- Choosing Wisely®: Things we do for no reasonJournal of Hospital Medicine, 2015
- No hacerAtencion Primaria, 2015